Veradermics
MANE | NYSE
$132.85
-$6.84 (-4.90%)
Nov 2, 2026, 1:13 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a |
Operating Income | -102.77M | -73.22M | -43.36M | -26.32M | -5.97M |
Interest Income | 8.3M | 3.46M | 977K | 280K | 209K |
Pretax Income | -92.68M | -69.18M | -41.95M | -25.76M | -5.66M |
Net Income | -92.68M | -69.18M | -41.95M | -25.76M | -5.66M |
Selling & General & Admin | 26.95M | 16.01M | 7.07M | 3.27M | 1.02M |
Research & Development | 75.82M | 57.21M | 36.29M | 23.05M | 4.95M |
Other Expenses | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 102.77M | 73.22M | 43.36M | 26.32M | 5.97M |
Interest Expense | 532K | 532K | 532K | 292K | 292K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 102.77M | 73.22M | 43.36M | 26.32M | 5.97M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 40.44M | 37.34M | 37.34M | n/a | 201.33M |
Shares Outstanding (Diluted) | 40.44M | 37.34M | 37.34M | n/a | 201.33M |
EPS (Basic) | -2.14 | -1.56 | -0.76 | -0.03 | -0.03 |
EPS (Diluted) | -2.14 | -1.56 | -0.76 | -0.03 | -0.03 |
EBITDA | -97.26M | -67.71M | -40.48M | -24.53M | -5.37M |
EBIT | -97.26M | -67.71M | -40.48M | -24.53M | -5.37M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove MANE